VEGFA and glioblastoma: A specific targeting based on an aptamer developed against the broadly expressed stromal product, the vascular endothelial growth factor (VEGF) [122], was used to bind GBM stroma, while the 4-1BB aptamer was used to bind the T-cell co-stimulatory receptor in order to induce the immune response activation.